Literature DB >> 21467041

The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivo.

Andrea N Flynn1, Dipti V Tillu, Marina N Asiedu, Justin Hoffman, Josef Vagner, Theodore J Price, Scott Boitano.   

Abstract

Protease-activated receptor-2 (PAR(2)) is one of four protease-activated G-protein-coupled receptors. PAR(2) is expressed on multiple cell types where it contributes to cellular responses to endogenous and exogenous proteases. Proteolytic cleavage of PAR(2) reveals a tethered ligand that activates PAR(2) and two major downstream signaling pathways: mitogen-activated protein kinase (MAPK) and intracellular Ca(2+) signaling. Peptides or peptidomimetics can mimic binding of the tethered ligand to stimulate signaling without the nonspecific effects of proteases. The most commonly used peptide activators of PAR(2) (e.g. SLIGRL-NH(2) and SLIGKV-NH(2)) lack potency at the receptor. However, although the potency of 2-furoyl-LIGRLO-NH(2) (2-f-LIGRLO-NH(2)) underscores the use of peptidomimetic PAR(2) ligands as a mechanism to enhance pharmacological action at PAR(2), 2-f-LIGRLO-NH(2) has not been thoroughly evaluated. We evaluated the known agonist 2-f-LIGRLO-NH(2) and two recently described pentapeptidomimetic PAR(2)-specific agonists, 2-aminothiazol-4-yl-LIGRL-NH(2) (2-at-LIGRL-NH(2)) and 6-aminonicotinyl-LIGRL-NH(2) (6-an-LIGRL-NH(2)). All peptidomimetic agonists stimulated PAR(2)-dependent in vitro physiological responses, MAPK signaling, and Ca(2+) signaling with an overall rank order of potency of 2-f-LIGRLO-NH(2) ≈ 2-at-LIGRL-NH(2) > 6-an-LIGRL-NH(2) ≫ SLIGRL-NH(2). Because PAR(2) plays a major role in pathological pain conditions and to test potency of the peptidomimetic agonists in vivo, we evaluated these agonists in models relevant to nociception. All three agonists activated Ca(2+) signaling in nociceptors in vitro, and both 2-at-LIGRL-NH(2) and 2-f-LIGRLO-NH(2) stimulated PAR(2)-dependent thermal hyperalgesia in vivo. We have characterized three high potency ligands that can be used to explore the physiological role of PAR(2) in a variety of systems and pathologies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467041      PMCID: PMC3099721          DOI: 10.1074/jbc.M110.185264

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Protease-activated receptors: how proteases signal to cells to cause inflammation and pain.

Authors:  Nigel W Bunnett
Journal:  Semin Thromb Hemost       Date:  2006-04       Impact factor: 4.180

2.  Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice.

Authors:  Silvia Amadesi; Graeme S Cottrell; Lorna Divino; Kevin Chapman; Eileen F Grady; Francisco Bautista; Rustum Karanjia; Carlos Barajas-Lopez; Stephen Vanner; Nathalie Vergnolle; Nigel W Bunnett
Journal:  J Physiol       Date:  2006-06-22       Impact factor: 5.182

3.  Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway.

Authors:  N Vergnolle; N W Bunnett; K A Sharkey; V Brussee; S J Compton; E F Grady; G Cirino; N Gerard; A I Basbaum; P Andrade-Gordon; M D Hollenberg; J L Wallace
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

4.  Molecular cloning of a potential proteinase activated receptor.

Authors:  S Nystedt; K Emilsson; C Wahlestedt; J Sundelin
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

5.  Sensitization of TRPA1 by PAR2 contributes to the sensation of inflammatory pain.

Authors:  Yi Dai; Shenglan Wang; Makoto Tominaga; Satoshi Yamamoto; Tetsuo Fukuoka; Tomohiro Higashi; Kimiko Kobayashi; Koichi Obata; Hiroki Yamanaka; Koichi Noguchi
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

6.  Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways.

Authors:  Rithwik Ramachandran; Koichiro Mihara; Maneesh Mathur; Moulay Driss Rochdi; Michel Bouvier; Kathryn Defea; Morley D Hollenberg
Journal:  Mol Pharmacol       Date:  2009-07-15       Impact factor: 4.436

7.  Identification and characterization of novel small-molecule protease-activated receptor 2 agonists.

Authors:  Luis R Gardell; Jian-Nong Ma; Jimmi Gerner Seitzberg; Anne E Knapp; Hans H Schiffer; Ali Tabatabaei; Christopher N Davis; Michelle Owens; Bryan Clemons; Kenneth K Wong; Birgitte Lund; Norman R Nash; Yan Gao; Jelveh Lameh; Kara Schmelzer; Roger Olsson; Ethan S Burstein
Journal:  J Pharmacol Exp Ther       Date:  2008-09-03       Impact factor: 4.030

8.  Multiple independent functions of arrestins in the regulation of protease-activated receptor-2 signaling and trafficking.

Authors:  Lisa Stalheim; Yu Ding; Anuradha Gullapalli; May M Paing; Breann L Wolfe; Dionne R Morris; JoAnn Trejo
Journal:  Mol Pharmacol       Date:  2004-10-08       Impact factor: 4.436

Review 9.  Neuropathic pain: a maladaptive response of the nervous system to damage.

Authors:  Michael Costigan; Joachim Scholz; Clifford J Woolf
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

10.  Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain.

Authors:  Yi Dai; Tomoko Moriyama; Tomohiro Higashi; Kazuya Togashi; Kimiko Kobayashi; Hiroki Yamanaka; Makoto Tominaga; Koichi Noguchi
Journal:  J Neurosci       Date:  2004-05-05       Impact factor: 6.167

View more
  15 in total

1.  Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time.

Authors:  Dong Guo; Thea Mulder-Krieger; Adriaan P IJzerman; Laura H Heitman
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

2.  Discovery of Novel Nonpeptidic PAR2 Ligands.

Authors:  Ilona Klösel; Maximilian F Schmidt; Jonas Kaindl; Harald Hübner; Dorothee Weikert; Peter Gmeiner
Journal:  ACS Med Chem Lett       Date:  2020-05-22       Impact factor: 4.345

3.  The cellular basis of protease-activated receptor 2-evoked mechanical and affective pain.

Authors:  Shayne N Hassler; Moeno Kume; Juliet M Mwirigi; Ayesha Ahmad; Stephanie Shiers; Andi Wangzhou; Pradipta R Ray; Serge N Belugin; Dhananjay K Naik; Michael D Burton; Josef Vagner; Scott Boitano; Armen N Akopian; Gregory Dussor; Theodore J Price
Journal:  JCI Insight       Date:  2020-06-04

4.  Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysis.

Authors:  Justin Hoffman; Andrea N Flynn; Dipti V Tillu; Zhenyu Zhang; Renata Patek; Theodore J Price; Josef Vagner; Scott Boitano
Journal:  Bioconjug Chem       Date:  2012-10-08       Impact factor: 4.774

5.  A highly potent agonist to protease-activated receptor-2 reveals apical activation of the airway epithelium resulting in Ca2+-regulated ion conductance.

Authors:  Cara L Sherwood; Michael O Daines; Theodore J Price; Josef Vagner; Scott Boitano
Journal:  Am J Physiol Cell Physiol       Date:  2014-10-15       Impact factor: 4.249

6.  Cerium dioxide (CeO2) nanoparticles decrease arsenite (As(III)) cytotoxicity to 16HBE14o- human bronchial epithelial cells.

Authors:  Chao Zeng; Chi Nguyen; Scott Boitano; Jim A Field; Farhang Shadman; Reyes Sierra-Alvarez
Journal:  Environ Res       Date:  2018-03-22       Impact factor: 6.498

7.  The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo.

Authors:  Scott Boitano; Justin Hoffman; Andrea N Flynn; Marina N Asiedu; Dipti V Tillu; Zhenyu Zhang; Cara L Sherwood; Candy M Rivas; Kathryn A DeFea; Josef Vagner; Theodore J Price
Journal:  Br J Pharmacol       Date:  2015-08-03       Impact factor: 8.739

8.  Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering.

Authors:  Andrea N Flynn; Justin Hoffman; Dipti V Tillu; Cara L Sherwood; Zhenyu Zhang; Renata Patek; Marina N K Asiedu; Josef Vagner; Theodore J Price; Scott Boitano
Journal:  FASEB J       Date:  2013-01-04       Impact factor: 5.191

9.  The MNK-eIF4E Signaling Axis Contributes to Injury-Induced Nociceptive Plasticity and the Development of Chronic Pain.

Authors:  Jamie K Moy; Arkady Khoutorsky; Marina N Asiedu; Bryan J Black; Jasper L Kuhn; Paulino Barragán-Iglesias; Salim Megat; Michael D Burton; Carolina C Burgos-Vega; Ohannes K Melemedjian; Scott Boitano; Josef Vagner; Christos G Gkogkas; Joseph J Pancrazio; Jeffrey S Mogil; Gregory Dussor; Nahum Sonenberg; Theodore J Price
Journal:  J Neurosci       Date:  2017-07-03       Impact factor: 6.167

10.  Protease-activated receptor-2 signaling through β-arrestin-2 mediates Alternaria alkaline serine protease-induced airway inflammation.

Authors:  Michael C Yee; Heddie L Nichols; Danny Polley; Mahmoud Saifeddine; Kasturi Pal; Kyu Lee; Emma H Wilson; Michael O Daines; Morley D Hollenberg; Scott Boitano; Kathryn A DeFea
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-18       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.